{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:22:51Z","timestamp":1787235771665,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:11:18Z","timestamp":1765404678000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors \u2013 A single centre experience"],"prefix":"10.1016","volume":"204","author":[{"given":"Italo","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Tavangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lafreniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"MacKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.12.003_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0015","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","article-title":"Reporting of immune checkpoint inhibitor-associated myocarditis","volume":"392","author":"Al-Kindi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0025","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0035","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0040","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"issue":"S1697","key":"10.1016\/j.ygyno.2025.12.003_bb0045","article-title":"Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2017.11.019","article-title":"The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study","volume":"148","author":"Kitson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.2023.13174","article-title":"Cervical cancer screening","volume":"330","author":"Perkins","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0060","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0735-1097(25)01194-5","article-title":"Human papillovirus infection and cardiovascular diseases: a meta-analysis of effect sizes from 249,366 patients","volume":"85","author":"Vilela","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0075","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0080","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0085","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0090","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis","volume":"85","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0100","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.12688\/f1000research.14857.1","article-title":"The unique role of cardiovascular magnetic resonance imaging in acute myocarditis","volume":"7","author":"Chetrit","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf147","article-title":"The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors","volume":"30","author":"Gvili Perelman","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis","volume":"85","author":"Drazner","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0125","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0130","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0135","series-title":"NCCN Clinical Practice Guidelines in Oncology: Management of Immune Checkpoint Inhibitor-Related Toxicities. Version 1.2026","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0140","article-title":"Serum troponin T concentrations are frequently elevated in advanced skin cancer patients prior to immune checkpoint inhibitor therapy: experience from a single tertiary referral center","volume":"8","author":"Kurzhals","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0145","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0150","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0735-1097(97)00317-3","article-title":"Cardiac troponin T in patients with clinically suspected myocarditis","volume":"30","author":"Lauer","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.035128","article-title":"Role of antitroponin antibodies and macrotroponin in the clinical interpretation of cardiac troponin","volume":"13","author":"Salaun","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0160","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaccao.2024.06.002","article-title":"Circulating macrotroponin complexes and their impact on cardiac troponin measurements","volume":"6","author":"Nardi-Agmon","year":"2024","journal-title":"JACC Cardio Oncol."},{"key":"10.1016\/j.ygyno.2025.12.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19274","article-title":"Immune checkpoint inhibitors and survival disparities by health insurance coverage among patients with metastatic cancer","volume":"8","author":"Zhao","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2025.12.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","journal-title":"Eur. Heart J."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:41:24Z","timestamp":1765406484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582501128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"alternative-id":["S009082582501128X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.12.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors \u2013 A single centre experience","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}